Same programs, opposite outcomes
Metabolic disease is adaptation exhaustion: the response is run continuously until the reserve is gone and the tissue loses function. Cancer is sustained adaptation: the response is kept on and becomes the driver of growth. The distinction is not which pathway is active but whether the cell can pause it.
The beta cell under chronic nutrient load
Continuous glucose and lipid excess forces sustained insulin synthesis. The ER secretory reserve falls, the UPR shifts toward its pro-apoptotic arm, and beta cell mass declines. The predicted outcome is progressive loss of secretory capacity, which matches the clinical course of type 2 diabetes.
Why trade-off costs become tumor vulnerabilities
A tumor cell running glycolysis, antioxidant defense, UPR, and autophagy simultaneously is spending its biosynthetic budget on all four at once. It has little reserve left. Interventions that add a second demand, such as raising ROS or blocking autophagic nutrient supply, can push it past its limit while normal cells with reserve survive.